The in vivo data obtained in the CLL-xenograft mouse model demonstrated that, by inducing PLCγ1-mediated, caspase-independent PCD, the injection of CD47 agonist peptides significantly reduced tumor burden. This evidence concerns the gene PLCG1 and B-cell chronic lymphocytic leukemia.